Zim Laboratories Ltd Q1 FY2024 Concall Summary

Key Takeaways

• Revenue hit by currency shortage, not demand destruction: Exports fell because management prudently refused to ship to ROW markets without advance payment amid a US dollar shortage; the underlying orders and contracts remain alive.
• Gross margin jumped to 48.4% on mix shift: High-margin NIP products, including first European oral thin film sales, lifted gross contribution from 43% a year ago, while lower-margin sales that did not ship also helped the mix.
• NIP strategy is now producing revenue, not just filings: NIP manufacturing and sales generated ₹4.7 crore in Q1, alongside dossier and licensing fees, marking the start of R&D payback after years of investment.
• Mid-teen growth guidance is under review, not withdrawn: Management says the target is still achievable but will provide a detailed revised view only after Q2, once the currency situation and order recovery become clearer.
• What to watch next quarter: Whether the PFI orders that shifted to Q2 actually convert, whether the nutraceutical customer confirms its LC and advance, and the revised full-year guidance.

Revenue Headwinds: Currency Shortage & Order Deferral

• Dollar shortage drove the decline: Revenue decreased primarily because of a drop in nutraceutical exports to certain ROW markets where US currency availability was constrained; the company's policy is not to ship without advance payment, so it chose not to proceed despite existing orders.
• PFI business shifted, not lost: A significant amount of pharmaceutical PFI business moved to the next quarter, hindering pharma export growth in Q1; orders have since come back and advances were received in Q2.
• Nutraceutical decline is unconfirmed: The ₹17.5 crore drop in nutraceuticals is not yet confirmed as lost sales because the customer has yet to confirm the LC and advance; management will be able to comment on recovery by the end of Q2.
• No market strategy shift: Management explicitly rejected the idea of shifting targeted markets because of the currency crisis, stating "we do not anticipate" such a change.
• Diversification was already underway: The company had already initiated engagement with other customers and is looking at Pharmerging and other markets for both Pharma and Nutra products; it has opened its own subsidiaries and is appointing its own marketing partners.

Dr. Anwar Daud: "the orders were there, but the postponement was mutual and the contract is still alive. And I think in the end, there is only one reason for why this order was postponed, that is the currency shortage and your company is prudent."

NIP & Oral Thin Film: The Margin Engine Starts

• First material NIP revenue: NIP products delivered ₹4.7 crore in manufacturing and sales revenue in Q1, in addition to dossier and licensing fees, marking the start of ROI from the R&D investment.
• European OTF supplies began: Revenue from oral thin film products came in from Europe this quarter, a milestone for the regulated-market strategy.
• Gross margin lifted by product mix: The 48.4% gross margin, up from 43% YoY, was driven by high-margin NIP products including oral thin films, plus the absence of some lower-margin product sales that did not ship in the quarter.
• Dossier engine is running: The company filed 20 NIP dossiers across Pharmerging and ROW markets in Q1, plus 6 oral thin film dossiers in the same regions; it and its partners received 5 marketing authorizations on ZIM's dossier.
• 4 more NIP filings targeted this year: The company is on track for 4 EU NIP filings this year, though management declined to provide new information on their status this quarter.
• OTF market is large and protected: The global OTF market is roughly \$6–7 billion, with the largest single product exceeding \$1 billion in revenue; management sees technology barriers as a durable moat, noting some products have faced no formidable competition for 30–60 years.

Dr. Anwar Daud: "R&D is the only way in which you can address the change, the rapid changes that are taking place in the pharmaceutical business and all around us. It is the right strategy because that is what will differentiate your company from the others."

Nutraceutical: Post-COVID Oversupply Pain

• First-year normalization after the surge: The nutraceutical business is experiencing pain because this is the first year of operation after the COVID-19 demand surge, and all players are now oversupplied; management expects this to even out.
• Underlying demand thesis intact: Management argues that prescribing habits and lifestyle habits do not change once established, so the nutraceutical story remains strong despite the current oversupply.
• Customer commitment still pending: The nutraceutical customer has yet to confirm its LC and advance, so the ₹17.5 crore decline is not yet classified as a lost sale; clarity is expected by the end of Q2.

Dr. Anwar Daud: "the nutraceutical story remains strong because prescribing habits and the lifestyle habits do not change once they catch hold, and we feel that nutraceutical we have a strong story for us."

Balance Sheet & Operational Efficiency

• Escrow liquidation strengthened the balance sheet: Liquidation of escrow sales brought in ₹30.6 crore, which was used to reduce borrowings and will lower finance costs in coming quarters.
• Operating costs reduced YoY: Alongside the gross margin improvement, operating costs declined year-on-year, reflecting what management called business model resilience and operational efficiency.
• CAPEX continues on planned lines: The company added ₹18.1 crore to its gross block in Q1, primarily for construction of a new warehouse that has now been completed; two other projects remain underway, with CAPEX on a similar trajectory to last year.

Market Access: New Geographies, Early Stage

• Australia and New Zealand entry: The company appointed marketing and distribution partners for Australia and New Zealand, a fresh start based on leveraging NIP and oral film products in select regulated markets; there is no current revenue contribution.
• First European supplies shipped: The quarter saw the first supplies to Europe, a milestone for the regulated-market strategy that is expected to deliver higher margins.
• Marketing authorizations received but not yet quantified: The company and its partners received 5 marketing authorizations in Europe and 5 in Pharmerging and ROW markets last quarter; management says it is too early to quantify the business impact and will provide specifics when contractual obligations permit.
• India OTF focus deprioritized: Management confirmed that OTF focus has shifted to Europe because the company is not getting the required traction or margins in India.

Guidance & Commitments

Key Metrics